Experimental cell therapy takes on COVID-19 lung crisis
Disease control
Completed
This early-stage trial tested a new cell therapy called agenT-797 in 20 hospitalized COVID-19 patients with moderate to severe breathing distress. The therapy uses immune cells from a healthy donor to calm inflammation and fight the virus. The main goals were to check safety and …
Phase: PHASE1 • Sponsor: MiNK Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC